FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904286341> ?p ?o ?g. }

• W2904286341 endingPage "32" @default.
• W2904286341 startingPage "17" @default.
• W2904286341 abstract "Docetaxel (DOC) is widely used as a chemotherapy drug for various tumors, including gastric cancer (GC), but the clinical application of DOC has been limited due to the hydrophobicity of the drug. We aimed to formulate a multifunctional nanoparticle (NP) system to reduce the side effects of the chemotherapy agent, to promote synergistic therapeutic effects, and to achieve targeted delivery of the therapy.The polyethylene glycol-poly(ε-caprolactone) NPs (PEG-PCL NPs) were prepared by a ring opening copolymerization technique and were then conjugated with a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb). The effects of the surface coating on particle size, size distribution, zeta potential, drug encapsulation efficiency, loading capacity, and the drug release kinetics were investigated. By using a panel of PD-L1-expressing human GC cell lines and PD-L1-overexpressing cells, we studied cellular uptake, cytotoxic effects, and cellular apoptosis in the presence of PD-L1 mAb-conjugated NPs.The characterization of the structure and biological functions of DOC-PEG-PCL-mAb NPs was investigated in vitro. X-ray photoelectron spectroscopy validated the presence of the PD-L1 mAbs on the NP surface. The cellular uptake analysis showed that the antibody-conjugated NPs achieved significantly higher cellular uptake. The results of an in vitro cytotoxicity experiment on three GC lines further proved the targeting effects of the antibody conjugation. In addition, we found that the DOC-PEG-PCL-mAb NPs induced cell apoptosis and enhanced G2-M arrest in cancer cells, indicating the inhibition of microtubule synthesis. When compared with the control groups, DOC-PEG-PCL-mAb NPs are more effective in inhibiting PD-L1 expression in GC cells.Our results reported here highlight the biological and clinical potential of DOC-PEG-PCL-mAb NPs using PD-L1 mAbs in GC treatment." @default.
• W2904286341 created "2018-12-22" @default.
• W2904286341 creator A5000970532 @default.
• W2904286341 creator A5008419499 @default.
• W2904286341 creator A5010877903 @default.
• W2904286341 creator A5014990417 @default.
• W2904286341 creator A5038297795 @default.
• W2904286341 creator A5045650596 @default.
• W2904286341 creator A5046436076 @default.
• W2904286341 creator A5073698613 @default.
• W2904286341 creator A5074221047 @default.
• W2904286341 creator A5076021895 @default.
• W2904286341 creator A5083206789 @default.
• W2904286341 date "2018-12-01" @default.
• W2904286341 modified "2023-10-10" @default.
• W2904286341 title "PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells" @default.
• W2904286341 cites W1534849470 @default.
• W2904286341 cites W1699918302 @default.
• W2904286341 cites W1964146045 @default.
• W2904286341 cites W1969765578 @default.
• W2904286341 cites W1972960507 @default.
• W2904286341 cites W1976269164 @default.
• W2904286341 cites W1982488143 @default.
• W2904286341 cites W1983240885 @default.
• W2904286341 cites W1984545852 @default.
• W2904286341 cites W1985106225 @default.
• W2904286341 cites W1992103975 @default.
• W2904286341 cites W1992768781 @default.
• W2904286341 cites W1999075493 @default.
• W2904286341 cites W2001498331 @default.
• W2904286341 cites W2015168077 @default.
• W2904286341 cites W2022399395 @default.
• W2904286341 cites W2030008772 @default.
• W2904286341 cites W2044253211 @default.
• W2904286341 cites W2054698826 @default.
• W2904286341 cites W2056893124 @default.
• W2904286341 cites W2057848113 @default.
• W2904286341 cites W2058369946 @default.
• W2904286341 cites W2060070314 @default.
• W2904286341 cites W2066671159 @default.
• W2904286341 cites W2068809055 @default.
• W2904286341 cites W2076452801 @default.
• W2904286341 cites W2077968480 @default.
• W2904286341 cites W2083982805 @default.
• W2904286341 cites W2085125246 @default.
• W2904286341 cites W2096616783 @default.
• W2904286341 cites W2100439220 @default.
• W2904286341 cites W2102449174 @default.
• W2904286341 cites W2104347254 @default.
• W2904286341 cites W2110415532 @default.
• W2904286341 cites W2111237964 @default.
• W2904286341 cites W2117838810 @default.
• W2904286341 cites W2128035403 @default.
• W2904286341 cites W2136859769 @default.
• W2904286341 cites W2148706833 @default.
• W2904286341 cites W2149984051 @default.
• W2904286341 cites W2156353875 @default.
• W2904286341 cites W2210453860 @default.
• W2904286341 cites W2272984102 @default.
• W2904286341 cites W2528647848 @default.
• W2904286341 cites W2538780230 @default.
• W2904286341 cites W2560367415 @default.
• W2904286341 cites W2572174216 @default.
• W2904286341 cites W2587897624 @default.
• W2904286341 cites W4211019965 @default.
• W2904286341 doi "https://doi.org/10.2147/ijn.s175340" @default.
• W2904286341 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6302817" @default.
• W2904286341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30587982" @default.
• W2904286341 hasPublicationYear "2018" @default.
• W2904286341 type Work @default.
• W2904286341 sameAs 2904286341 @default.
• W2904286341 citedByCount "61" @default.
• W2904286341 countsByYear W29042863412019 @default.
• W2904286341 countsByYear W29042863412020 @default.
• W2904286341 countsByYear W29042863412021 @default.
• W2904286341 countsByYear W29042863412022 @default.
• W2904286341 countsByYear W29042863412023 @default.
• W2904286341 crossrefType "journal-article" @default.
• W2904286341 hasAuthorship W2904286341A5000970532 @default.
• W2904286341 hasAuthorship W2904286341A5008419499 @default.
• W2904286341 hasAuthorship W2904286341A5010877903 @default.
• W2904286341 hasAuthorship W2904286341A5014990417 @default.
• W2904286341 hasAuthorship W2904286341A5038297795 @default.
• W2904286341 hasAuthorship W2904286341A5045650596 @default.
• W2904286341 hasAuthorship W2904286341A5046436076 @default.
• W2904286341 hasAuthorship W2904286341A5073698613 @default.
• W2904286341 hasAuthorship W2904286341A5074221047 @default.
• W2904286341 hasAuthorship W2904286341A5076021895 @default.
• W2904286341 hasAuthorship W2904286341A5083206789 @default.
• W2904286341 hasBestOaLocation W29042863411 @default.
• W2904286341 hasConcept C10138342 @default.
• W2904286341 hasConcept C109316439 @default.
• W2904286341 hasConcept C121608353 @default.
• W2904286341 hasConcept C12554922 @default.
• W2904286341 hasConcept C126322002 @default.
• W2904286341 hasConcept C159654299 @default.
• W2904286341 hasConcept C162324750 @default.
• W2904286341 hasConcept C171250308 @default.

• next